MK2-IN-3

• Description:

  MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC50s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC50s>200 μM) . MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  MAPKAPK2 (MK2)

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/mk2-in-3.html

• Concentration:

  10mM

• Purity:

  99.70

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  O=C1C2=C(NC(C3=CC(C4=CC5=CC=CC=C5N=C4)=NC=C3)=C2)CCN1

• Molecular Formula:

  C21H16N4O

• Molecular Weight:

  340.39

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Anderson DR, et, al. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2) . J Med Chem. 2007 May 31;50 (11) :2647-54.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [724711-21-1]